Interferon: An unfolding tale

Journal of Interferon and Cytokine Research

Volumn 27, Issue 6, 2007, Pages 447-452

  Gresser, Ion ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CYTOKINE; INTERFERON;

ANIMAL CELL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; CONTROLLED STUDY; GLOMERULONEPHRITIS; HISTORY OF MEDICINE; HUMAN; INTERFERON PRODUCTION; LIVER NECROSIS; LYMPHOCYTE CULTURE; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MEDICAL RESEARCH; MOUSE; NONHUMAN; PICHINDE ARENAVIRUS; PRIORITY JOURNAL; REVIEW; SENDAI VIRUS; VIRUS INFECTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; DISEASE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INTERFERONS; NEOPLASMS; VIRUS DISEASES;

EID: 34250859385     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2007.9986     Document Type: Review

References (61)

1. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B 1957;147:258-267.
2. Gresser I. Three remarkable teachers. J. Interferon Cytokine Res. 2000;20:609-611.
3. Ho M, Enders JF. An inhibitor of viral activity appearing in infected cell cultures. Proc. Natl. Acad. Sci. USA 1959;45:385-389.
4. De Maeyer E, Enders JF. An interferon appearing in cell cultures infected with measles virus. Proc. Soc. Exp. Biol. Med. 1961;107: 573-578.
5. Baron S, Isaacs A. Absence of interferon in lungs from fatal cases of influenza. Br. Med. J. 1962;1:18-20.
6. Gresser I, Dull HB. A virus inhibitor in pharyngeal washings from patients with influenza. Proc. Soc. Exp. Biol. Med. 1964;115: 192-196.
7. Gresser I, Naficy K. Recovery of an interferon-like substance from cerebrospinal fluid. Proc. Soc. Exp. Biol. Med. 1964;117:285-289.
8. Stewart WE. The Interferon System. Wien, New York: Springer-Verlag, 1979:1-421.
9. Gresser I. Production of interferon by suspensions of human leukocytes. Proc. Soc. Exp. Biol. Med. 1961;108:799-803.
10. Cantell K. Why is interferon not in clinical use today? In: Gresser I, ed. Interferon. London: Academic Press, 1976:1;2-28.
11. Finter NB. A rich source of mouse interferon. Nature 1964;204: 1114-1115.
12. Gresser I, Bourali C, Thomas M-T, Falcoff E. Effect of repeated inoculation of interferon preparations on infection of mice with encephalomyocarditis virus. Proc. Soc. Exp. Biol. Med. 1968;127: 491-496.
13. Gresser I, Fontaine-Brouty-Boye D, Bourali C, Thomas M-T. Efficacy of endogenous, exogenous and combined endogenous-exogenous interferon in the treatment of mice infected with encephalomyocarditis virus. Proc. Soc. Exp. Biol. Med. 1969;130: 236-242.
14. Gresser I. Wherefore interferon? J. Leuk. Biol. 1997;61:567-574.
15. Tovey M, Begon-Lours J, Gresser I. A method for the large-scale production of potent interferon preparations. Proc. Soc. Exp. Biol. Med. 1974;146:809-815.
16. De Maeyer-Guignard J, Tovey MG, Gresser I, De Maeyer E. Purification of mouse interferon by sequential affinity chromatography on poly (U) and antibody-agarose columns. Nature 1978;271: 622-625.
17. Gresser I. Role of interferon in resistance to viral infection in vivo. In: DeMaeyer E, Vilcek J, eds. Interferons II: Interferon and the Immune System. Amsterdam: Elsevier Science Biomedical Publishers, 1984:221-247.
18. Muller U, Steinhoff U, Reiss LFL, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M. Functional role of type I and II interferons in antiviral defense. Science 1994;264:1918-1921.
19. Dupuis S, Jouanguy E, Al-Haijar S, Fieschi C, Al-Hohsen IZ, Al-Jumaah S, Yang K, Chapgier A, Eidenschenk C, Eid P, Al Ghonaium A, Tufenkeji H, Frayha H, Al-Gazlan S, Al-Rayes H, Schreiber RD, Gresser I, Casanova JL. Impaired response to interferon-α/β and lethal viral disease in human Stat1 deficiency. Nat.Genet. 2003;33:388-391.
20. Gresser I, Coppey J, Fontaine-Brouty-Boye D, Falcoff E, Falcoff R, Zajdela F, Bourali C, Thomas M-T. The effect of interferon preparations on Friend leukemia in mice. CIBA Found. Symp. Interferon 1967;240-248.
21. Gresser I, Coppey J, Bourali C. Interferon and murine leukemia. VI. The effect of interferon preparations on the lymphoid leukemia of AKR mice. J. Natl. Cancer Inst. 1969;43:1083-1089.
22. Gresser I, Bourali C, Lévy JP, Fontaine-Brouty-Boye D, Thomas M-T. Increased survival in mice inoculated with tumor cells and treated with interferon preparations. Proc. Natl. Acad. Sci. USA 1969;63:51-57.
23. Gresser I, Tovey MG. Antitumor effects of interferon. Biochim. Biophys. Acta 1978;516:231-247.
24. Gresser I. Antitumor effects of interferon. In: Becker F, ed. Cancer - A Comprehensive Treatise. New York: Plenum Press, 1977;5: 521-571.
25. Gresser I. How does interferon inhibit tumor growth? Phil. Trans. R. Soc. Lond. 1982;B299:69-76.
26. Gresser I, De Maeyer-Guignard J, Tovey MG, De Maeyer E. Electrophoretically pure mouse interferon exerts multiple biologic effects. Proc. Natl. Acad. Sci. USA 1979;76:5308-5312.
27. Gresser I, Bandu MT, Brouty-Boye D. Interferon and cell division. IX. Interferon-resistant L1210 cells: characteristics and origin. J. Natl. Cancer Inst. 1974;52:553-559.
28. Gresser I, Maury C, Brouty-Boyé D. On the mechanism of the antitumour effect of interferon in mice. Nature 1972;239:167-168.
29. Gresser I. How does interferon inhibit tumor growth? In: Gresser I, ed. Interferon 6. New York, London: Academic Press, 1985;6:93-126.
30. Gresser I. The antitumor effects of interferon. Med. Oncol. Tumor Pharmacother. 1986;3:223-230.
31. Gresser I, Carnaud C, Maury C, Sala A, Eid P, Woodrow D, Maunoury M-T, Belardelli F. Host humoral and cellular immune mechanisms in the continued suppression of Friend erythroleukemia metastases after interferon α/β treatment in mice. J. Exp. Med. 1991;173:1193-1203.
32. Ferrantini M, Proietti E, Santodonato L, Gabriele L, Peretti M, Plavec I, Meyer F, Kaido T, Gresser I, Belardelli F. α1-Interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice. Antitumor therapy by means of interferon-producing cells. Cancer Res. 1993;53:1107-1112.
33. Kaido T, Bandu M-T, Maury C, Ferrantini M, Belardelli F, Gresser I. IFN-α1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57B1/6 mice. Int. J. Cancer 1995;60:221-229.
34. Gabriele L, Kaido T, Woodrow D, Moss J, Ferrantini M, Proietti E, Santodonato L, Rosera C, Maury C, Belardelli F, Gresser I. The local and systemic response of mice to interferon α1 transfected Friend leukemia cells. Am. J. Pathol. 1995;147:445-460.
35. Strander H. Interferon treatment of human neoplasia. Adv. Cancer Res. 1986;46:1-265.
36. Gutterman U. Cytokine therapeutics: lessons from interferon α. Proc. Natl. Acad. Sci. USA 1994;91:1198-1205.
37. Gresser I. On the varied biologic effects of interferon. Cell. Immunol. 1977;34:406-415.
38. Burke DC, Isaacs A. Some factors affecting the production of interferon. Br. J. Exp. Pathol. 1958;39:452-458.
39. Stewart WE II, Gosser LB, Lockhart RZ. Priming: a non-antiviral function of interferon. J. Virol. 1971;7:792-801.
40. Gresser, I. Metamorphosis of human amnion cells induced by preparations of interferon. Proc. Natl. Acad. Sci. USA 1961;47: 1817-1822.
41. Paucker K, Cantell K, Henle W. Quantitative studies on viral interference in suspended L cells III. Effect of interfering viruses and interferon on the growth rate of cells. Virology 1962;17:324-334.
42. Gresser I. Effects of interferon on the expression of surface antigens. In: De Maeyer E, Vilcek J, eds. Interferons II. Interferon and the Immune System. Amsterdam: Elsevier Science Biomedical Publishers, 1984:113-132.
43. Brouty-Boyé D. Interferon and the tumour cell phenotype. In: Gresser I, ed. Interferon. London-New York: Academic Press, 1986;7:145-165.
44. Gresser I. Interferon and the immune system. Prog. Immunol. 1980; 40:710-719.
45. Belardelli F, Gresser I. The neglected role of type I interferon in the T cell response: implications for its clinical use. Immunol. Today 1996;17:369-372.
46. Frayssinet C, Gresser I, Tovey M, Lindahl P. Inhibitory effect of potent interferon preparations on the regeneration of mouse liver after partial hepatectomy. Nature 1973;245:146-147.
47. Gresser I, Tovey M, Maury C, Chouroulinkov I. Lethality of interferon preparations for newborn mice. Nature 1975;258:76-78.
48. Gresser I. Can interferon induce disease? In: Gresser I, ed. Interferon. 1982;4:95-127.
49. Morel-Maroger L, Sloper JC, Vinter J, Woodrow D, Gresser I. An ultrastructural study of the development of nephritis in mice treated with interferon in the neonatal period. Lab. Invest. 1978;39: 513-522.
50. Gresser I, Aguet M, Morel-Maroger L, Woodrow D, Puvion-Dutilleul F, Guillon J-C, Maury C. Electrophoretically pure mouse interferon inhibits growth, induces liver and kidney lesions and kills suckling mice. Am. J. Pathol. 1981;102:396-402.
51. Woodrow D, Moss I, Gresser I. Interferon induces pulmonary cysts in A2G mice. Proc. Natl. Acad. Sci. USA 1984;81:7937-7940.
52. Rivière Y, Gresser I, Guillon J-C, Tovey MG. Inhibition by anti-interferon serum of lymphocytic choriomeningitis virus disease in suckling mice. Proc. Natl. Acad. Sci. USA 1977;74:2135-2139.
53. Gresser I, Morel-Maroger L, Verroust P, Rivière Y, Guillon J-C. Anti-interferon globulin inhibits the development of glomerulonephritis in mice infected at birth with lymphocytic choriomeningitis virus. Proc. Natl. Acad. Sci. USA 1978;75:3413-3416.
54. Rivière Y, Gresser I, Guillon J-C, Bandu M-T, Ronco P, Morel-Maroger L, Verroust P. Severity of LCM virus disease in different strains of suckling mice correlates with increasing amounts of endogenous interferon. J. Exp. Med. 1980;152:633-640.
55. Bocci V. The physiological interferon response. Immunol. Today 1985;6:7-9.
56. Belardelli F, Vignaux F, Proietti E, Gresser I. Injection of mice with antibody to interferon renders peritoneal macrophages permissive for vesicular stomatitis and encephalomyocarditis virus. Proc. Natl. Acad. Sci. USA 1984;81:602-606.
57. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001;14:461-470.
58. Gresser I, Maury C, Kaido T, Bandu M-T, Tovey MG, Maunoury M-T, Fantuzzi L, Gessani S, Greco G, Belardelli F. The essential role of endogenous IFN α/β in the antimetastatic action of sensitized T lymphocytes in mice injected with Friend erythroleukemia cells. Int. J. Cancer 1995;63:726-731.
59. Gresser I, Maury C, Vignaux F, Haller O, Belardelli F, Tovey MG. Antibody to mouse interferon α/β abrogates resistance to the multiplication of Friend erythroleukemia cells in the livers of allogeneic mice. J. Exp. Med. 1988;168:1271-1291.
60. Gresser I, Belardelli F. Endogenous type I interferons as a defense against tumors. Cytokine Growth Factors 2002;13: 111-118.
61. Picaud S, Bardot B, De Maeyer E, Seif I, Enhanced tumor development in mice lacking a functional type I interferon receptor. J. Interferon Cytokine Res. 2002;22:457-462.